Adams Law

www.adamslaw.us

Speaking Engagements
(selected)

  • October 19, 2016, "ANDAs, Patents, and Exclusivities" at the Food and Drug Law Institute
  • September 20, 2016, "Recent Developments Regarding 5-Year, 3-Year, and 180-Day Exclusivity" at the American Conference Institute Paragraph IV Disputes Master Symposium
  • September 30, 2015, “The Nature of the Approval Process: Drugs” at the American Conference Institute, September 30, 2015
  • July 22, 2015, "Exclusivities, Opportunities, and Controversies" at the American Conference Institute
  • June 25, 2015, "The FDA Regulatory Paradigm" at the FDAnews Social Media Regulatory Affairs Summit
  • May 28, 2015, "ANDAs, Patents, and Exclusivities" at the Food and Drug Law Institute
  • March 10, 2015, "The Nature of the Drug and Biologic Approval Process" at the American Conference Institute
  • October 21, 2014, "Advertising, Promotion and Post Market Considerations" at the Food and Drug Law Institute
  • September 27, 2014, "OTC Drug Approval Paradigms" at the American Conference Institute
  • June 17, 2014, "FDA Deeming Regulations" for the Tobacco Merchants Association
  • April 2, 2014, "FDA's Regulatory Processes" at the Food and Drug Law Institute
  • March 12, 2014, "ANDAs, Patents and Exclusivities" at the American Conference Institute
  • March 12, 2014, "FDA Regulation of Generic Drugs under Hatch-Waxman" at the American Conference Institute's FDA Boot Camp Conference
  • November 26, 2013, "Exclusivities, Opportunities, and Controversies" at the Food and Drug Law Institute
  • November 6, 2013, "FDA regulation of Branded and Generic Drugs under Hatch-Waxman" at the Food and Drug Law Institute Drug Law and Regulation Conference
  • October 28, 2013, "Plan B® and a New Paradigm for OTC Drug Availability" at ACI's Legal, Regulatory and Compliance Forum on Over the Counter Drugs
  • June 26, 2013, "Claim Substantiation and Risk Mitigation in Dietary Supplement Advertising and Promotion: Exploring the Fine Line Between Structure Function and Disease Claims" at ACI's Legal, Regulatory and Compliance Forum on Dietary Supplements
  • April 26, 2013, "Social Media: FDA Speaks (a Wee Bit)" for the Independent Cosmetic Manufacturers and Distributors
  • April 4, 2013, "FDA Regulation of Drug and Biologic Advertising and Labeling" at the Food and Drug Law Institute Introduction to Drug Law Conference
  • March 20, 2013, "Exclusivities, Opportunities, and Controversies" at the American Conference Institute's FDA Boot Camp Conference
  • October 18, 2012, "The New Paradigm" at the American Conference Institute's Legal, Regulatory and Compliance Forum on Over the Counter Drugs
  • October 11, 2012, "Strategies Related to the OTC Switch" at the American Conference Institute's 13th Annual Maximizing Pharmaceutical Patent Life Cycles Conference
  • October 3, 2012, "Current Legal Issues Facing the Generic Industry" for the Generic Pharmaceutical Association Fall Technical Conference
  • July 17, 2012, "Brand Development Through IP in the Clinical Testing Phase" for the Food & Drug Law Institute
  • June 26, 2012, "An In-Depth Look at 180-Day Exclusivity," American Conference Institute's Hatch-Waxman Boot Camp
  • April 26, 2012, "Meet the Experts – Learn About Compliance Issues," ICMAD 31st FDA Cosmetic Regulations Workshop
  • November 16, 2011, "Biosimilar Labeling Issues" at the Food and Drug Law Institute Biosimilars Naming and Labeling Program 2011 International Convention
  • June 28, 2011, "Navigating the New Law on Licensing Biosimilars" at the BIO 2011 International Convention
  • June 28, 2011, "Talking About Your Product in the New Age: Social Media and the Internet" at the BIO 2011 International Convention
  • June 13, 2011, "Globalization of Clinical Trials, Data Integrity and Pre-Market Approvals" at the Food and Drug Law Institute's US-China Conference
  • April 28, 2011, FDA Workshop NYC, Independent Cosmetic Manufactures and Distributors (ICMAD)
  • March 16, 2011, "The Drug and Biologic Approval Processes" at the American Conference Institute
  • July 21, 2010, "The New Biosimilars Framework: Outlining the Issues as FDA Begins Implementation" webinar for The Food and Drug Law Institute
  • June 29, 2010, "Navigating the New Law on Licensing Biosimilars" Webinar, presented by Venable LLP
  • April 29, 2010, FDA Cosmetic Regulations Workshop
  • March 24, 2010, "Drug and Biologic Approval" at the American Conference Institute
  • March 3, 2010, "Social Media and the Internet" at the Annual Meeting of the New York State Bar Association
  • December 8, 2009, "FDA Regulation of Marketing" at the FDA Fellow Program
  • November 6, 2009, "Regulation of Drug Marketing" at the FDLI Drug Law Workshop
  • February 5, 2009, "Generic Drug Approval Issues" at the FDLI Program on Hatch-Waxman
  • June 5, 2008, "Marketing Biologics" at the Food and Drug Law Institute Introduction to Biotechnology Law
  • June 11, 2007, "Patents, Exclusivity, and Generic Drugs" at the Food and Drug Law Institute
  • April 13, 2007, “Regulation of Follow-On Biologics” at the Food and Drug Law Institute Annual Meeting
  • April 12, 2007, "Regulation of the Follow-On Biologics" at the 50th Annual FDLI and FDA Conference
  • March 27, 2007, Tech Counsel of Maryland General Counsel's Roundtable
  • 2006, "Recent Cases Involving Promotion of Off-Label Use" at the Thompson Interactive Audio Program
  • 2006, "Legislative Proposals Regarding Follow-On (Generic) Biologics" at the Food and Drug Law Institute Annual Meeting
  • 2006, "How an Off-Label Use Becomes Your Intended Use" at the Center for Business Intelligence Annual Program
  • 2006, "Liability for Off-Label Promotion" at the HCPro Audioconference
  • 2006, "Regulation of Drug and Biologic Marketing" at the Food and Drug Law Institute
  • 2006, “Patents, Exclusivity, and Generic Drugs” at the Food and Drug Law Institute
  • 2006, "Recent Cases Involving Promotion of Off-Label Use" at Thompson Publishing
  • 2006, “Introduction to Drug Law” at the Food and Drug Law Institute
  • 2006, “Legislative Proposals Regarding Follow-On Biologics” at the Food and Drug Law Institute
  • 2006, “A Question of Intent” at the Center for Business Intelligence
  • 2005, “NDAs, ANDAs, Patents, and Exclusivity” at the Food and Drug Law Institute
  • 2005, “Regulatory Liability Based on Support for CME” at the Medical Education Congress
  • 2005, “Regulatory Liability Based on Intended Use” at the Drug Information Association
  • 2004, "Product Life Cycle Management" at the Pharmaceutical Education Association
  • June 15, 2004, “Enforcement Beyond the FDZ: Justice Department, Attorneys General and HHS IG” at the Drug Information Association Annual Meeting
  • June 14, 2004 - June 15, 2004, FDLI's Introduction to Drug Law and Regulation Workshop
  • 2004, “Current Issues in Regulation of Continuing Medical Education” at the Drug Information Association
  • 2004, “Product Life Cycle Management” at the Pharmaceutical Education Association
  • 2004, “Disseminating Product Information Prior to Approval” at the American Conference Institute
  • 2004, “FDA Regulation of Marketing” at the Food and Drug Law Institute
  • 2003, "Current Issues in FDA Regulation of Prescription Drug Promotion" at the Drug Information Association
  • 2003, “Current Issues in FDA Regulation of Prescription Drug Promotion” at the Drug Information Association
  • 2002, “Constitutional Limitations on FDA Regulation of Promotion” at the Federalist Society
  • 2002, “FDA’s First Amendment Review” at the Food and Drug Law Institute
  • 2002, “FDA Regulation of Drug Marketing” at the Drug Information Association
  • 2001, “Industry-Supported Information on Therapeutic Products” at the American Medical Association
  • 2001, “Current FDA Enforcement of Drug Advertising Requirements” at the Drug Information Association
  • 2001, “Pre-Approval Promotion: How to Do It Legally” at the Drug Information Association
  • 2000, “Federal Regulation of Drug Information on the Internet” at the American Conference Institute
  • 2000, “Constitutional Challenges to FDA Implementation of FDAMA” at the Drug Information Association2000, “Current FDA Enforcement of Drug Advertising Requirements” at the Drug Information Association